Clinical Trials
10 trialsNCT04316117 2026-05-05
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05710328 2026-05-05
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT07285993 2026-05-01
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04692103 2026-01-22
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
Phase 2 Active not recruiting
NCT02317783 2024-11-20
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
University of Utah
Phase 2 Terminated
NCT05396118 2024-05-14
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
Phase 2 Unknown
NCT00602043 2020-02-19
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02455453 2020-01-14
Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
Washington University School of Medicine
Phase 2 Completed
NCT02599194 2019-01-03
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University
Phase 2 Completed